# PDUFA dates January 2028: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2028-01

> 21 FDA catalysts are dated in January 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in January 2028

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 2028 | [Maridebart cafraglutide primary completion](https://sec-api.dev/pdufa/maridebart-cafraglutide) | AMGN | Obesity or Overweight | scheduled | "NCT07575399 (Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-03 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07575399)) |
| January 2028 | [Depemokimab primary completion](https://sec-api.dev/pdufa/depemokimab) | GSK | Asthma | scheduled | "NCT06979323 (Depemokimab Asthma Imaging and Bronchoscopy Sub-Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979323)) |
| January 2028 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Cutaneous Squamous Cell Carcinoma | scheduled | "NCT03969004 (Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-07 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03969004)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Renal Cell Carcinoma | scheduled | "NCT06307431 (A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307431)) |
| January 2028 | [TRUXIMA® (rituximab) primary completion](https://sec-api.dev/pdufa/rituximab) | BMY | Lymphoma | scheduled | "NCT07015242 (A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-09 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015242)) |
| January 2028 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Endometrial Cancer | scheduled | "NCT06132958 (Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132958)) |
| January 2028 | [ABP-234 primary completion](https://sec-api.dev/pdufa/abp-234) | AMGN | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | scheduled | "NCT06311721 (A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06311721)) |
| January 2028 | [Anifrolumab (blinded) primary completion](https://sec-api.dev/pdufa/anifrolumab-blinded) | AZN | Polymyositis, Dermatomyositis | scheduled | "NCT06455449 (A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06455449)) |
| January 2028 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Colitis, Ulcerative | scheduled | "NCT07196748 (A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196748)) |
| January 2028 | [AZD0292 primary completion](https://sec-api.dev/pdufa/azd0292) | AZN | Bronchiectasis With Pseudomonas Aeruginosa Colonization | scheduled | "NCT07774403 (A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07774403)) |
| January 2028 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07685808 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07685808)) |
| January 2028 | [Ponsegromab primary completion](https://sec-api.dev/pdufa/ponsegromab) | PFE | Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma | scheduled | "NCT06989437 (A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01-23 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989437)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06345729)) |
| January 2028 | [ABP-206 primary completion](https://sec-api.dev/pdufa/abp-206) | AMGN | Melanoma | scheduled | "NCT06054555 (A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06054555)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06170788 (Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06170788)) |
| January 2028 | [BNT116 primary completion](https://sec-api.dev/pdufa/bnt116) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05557591 (A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-26 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05557591)) |
| January 2028 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Borreliosis | scheduled | "NCT07226882 (A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226882)) |
| January 2028 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Functional Hypothalamic Amenorrhea; FHA | scheduled | "NCT07235917 (A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235917)) |
| January 2028 | [AMG-732 primary completion](https://sec-api.dev/pdufa/amg-732) | AMGN | Thyroid Eye Disease | scheduled | "NCT07438405 (An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-29 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07438405)) |
| January 2028 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Beta-Thalassemia | scheduled | "NCT04143724 (Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04143724)) |
| January 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Graves' Disease | scheduled | "NCT07722546 (A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722546)) |

Other months: https://sec-api.dev/fda-calendar/2027-12 , https://sec-api.dev/fda-calendar/2028-02. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates January 2028: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2028-01

```bibtex
@misc{secapidev_fda_calendar_2028_01_20261116,
  title        = {PDUFA dates January 2028: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2028-01}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2028_01_20261116","title":"PDUFA dates January 2028: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2028-01","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
